Europe to Spend USD 18 Million in Monkeypox Testing by the End of 2023 – Arizton

More than 25,300 confirmed Monkeypox cases in Europe (November 2022), the Demand for Monkeypox Testing Tremendously Increasing

CHICAGO, Feb. 9, 2023 /PRNewswire/ — According to Arizton’s latest research report, the Europe monkeypox testing market to spend USD 18 million by the end of 2023. Growing development of rapid testing methods, advancements in PCR technology, and increasing collaborations among the vendors are the growing trends in the market.

There are only a few MPX test kits available in the market. However, governments make efforts to control the virus due to its rapid spread across the region. As case numbers and surveillance measures increase, the MPX testing market is anticipated to grow substantially in the coming months. The Monkeypox outbreak gives companies huge opportunities to develop new diagnostics to detect MPXV. In September 2022, Cosmos Health, a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, over-the-counter (OTC) medications, and medical devices, announced that it entered a contract with Virax Biolabs, a UK-based diagnostics company, focused on the prevention and detection of viral diseases wherein, Virax Biolabs became the distributor of MPXV real-time PCR detection kits. Cosmos Health has exclusive distribution rights for Cyprus and Greece, with the opportunity to distribute test kits across Europe.

Europe Monkeypox Testing Market Report Scope

 

Click Here to Download the Free Sample Report

Increasing Development by Several vendors is driving the Europe monkeypox testing market growth

• In July 2022, ELITechGroup, a France-based privately held manufacturer and distributor of IVD equipment, strategically partnered with Jiangsu Bioperfectus Technologies for monkeypox virus testing across Europe.
• In June 2022, Eurobio Scientific launched a CE-marked monkeypox screening test available for hospital use in France.
• On 8th June 2022, altona Diagnostics, a medical diagnostic company headquartered in Germany, announced the launch of the RealStar Zoonotic Orthopoxvirus PCR Kit 1.0, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species-specific DNA – including MPVX DNA of the Central and West African strains.
• On 27th June 2022, Cepheid collaborated with the UK-based global molecular diagnostics company BioGX and announced a partnership between the two companies to provide a PCR test for MPX that will run on the GeneXpert system.
• In July 2022, the altona Diagnostics company launched another monkeypox virus detection kit, Flexstar Monkeypox virus PCR Detection Mix 1.5, for research purposes.
• Bioactiva Diagnostica is another Germany-based company that offers PCR kits for monkeypox virus detection.

Europe Monkeypox Testing Market Insights

• Syndromic tests for monkeypox detection are expected to witness strong growth because they can distinguish monkeypox from other harmful diseases, allowing for easier treatment. On 25th May 2022, Roche and its subsidiary TIB Molbiol announced that they had developed a unique LightMix Modular Virus kit that simultaneously detects orthopoxvirus and offers information on whether an MPXV is present or not, including all MPXV from both the West African and Central African forms of the virus.
• Rapid tests in the Europe monkeypox testing market are also expected to witness strong growth due to their rapid results and increasing consumer preference.
• Demand for MPXV testing kits is expected to decline during the forecast as the cases can be seen declining due to increased surveillance, contact tracing, and increasing vaccination across Europe.

Key Company Profiles

• Hoffmann-La Roche
• Qiagen
• altona Diagnostics
• Autobio
• Applied DNA Sciences
• Aurora Biomed
• bioactiva diagnostica
• Beijing Hotgen Biotech
• BioGX
• CERTEST BIOTEC
• Creative Biogene
• CorDx
• CLONIT
• Eurobio Scientific
• FireGene
• GenScript
• Guangzhou Pluslife Biotech
• JOYSBIO (Tianjin) Biotechnology
• Nanjing Synthgene Medical Technology
• RayBiotech Life
• Sansure Biotech
• Virax Biolabs
• Wondfo
• Shanghai Biogerm Medical Technology

Market Segmentation

Type

• PCR
• Lateral Flow Assay
• Others

End-User

• Laboratories
• Hospitals & Clinics
• Others

Region

• Europe
• EU-5
• Spain
• France
• UK
• Germany
• Italy
• Central, Eastern, and Southern Europe
• Netherlands
• Portugal
• Switzerland
• Nordic
• Sweden
• Denmark

Check Out Some of the Top-Selling Research Related Reports:

In Vitro Diagnostics Market – The global in vitro diagnostics market size crossed USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028.

HIV Rapid Test Kits Market – The global HIV rapid test kits market size was valued at USD 1.437 billion in 2022 and is expected to reach USD 1.68 billion by 2028.

COVID-19 Rapid Antigen Test Kits Market – The global COVID-19 rapid antigen tests market was valued at USD 4 billion in 2021 and is expected to reach USD 743.07 million by 2027.

Hematology Diagnostics Market – The hematology diagnostics market size was valued at USD 3 billion in 2021 and is expected to reach USD 4 billion by 2027.

Table of Content

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY TYPE

4.3.2 MARKET SEGMENTATION BY END-USER

4.3.3 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

6.1 OVERVIEW

7 MARKET AT A GLANCE

8 INTRODUCTION

8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

9.1 DEVELOPMENT OF RAPID TESTING METHODS

9.2 ADVANCES IN PCR TECHNOLOGY

9.3 VENDOR COLLABORATIONS

10 MARKET GROWTH ENABLERS

10.1 INCREASED GOVERNMENT SURVEILLANCE

10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS

10.3 INCREASED PRODUCT LAUNCHES

11 MARKET RESTRAINTS

11.1 DECLINE IN MPX CASES

11.2 MPX VACCINE APPROVAL & ACCESS

11.3 FALSE MPX TEST RESULTS

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.1.1 INSIGHTS BY TYPE

12.1.2 INSIGHTS BY END-USER

12.1.3 INSIGHTS BY GEOGRAPHY

12.2 FIVE FORCES ANALYSIS

12.2.1 THREAT OF NEW ENTRANTS

12.2.2 BARGAINING POWER OF SUPPLIERS

12.2.3 BARGAINING POWER OF BUYERS

12.2.4 THREAT OF SUBSTITUTES

12.2.5 COMPETITIVE RIVALRY

13 TEST TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 PCR

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.4 LATERAL FLOW ASSAYS

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.5 OTHERS

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

14 END-USER

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 LABORATORIES

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.4 HOSPITALS & CLINICS

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.5 OTHERS

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

15 GEOGRAPHY

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 MARKET OVERVIEW

16 EU-5

16.1 MARKET OVERVIEW

16.2 MARKET SIZE & FORECAST

16.3 KEY COUNTRIES

16.3.1 SPAIN: MARKET SIZE & FORECAST

16.3.2 FRANCE: MARKET SIZE & FORECAST

16.3.3 UK: MARKET SIZE & FORECAST

16.3.4 GERMANY: MARKET SIZE & FORECAST

16.3.5 ITALY: MARKET SIZE & FORECAST

17 CENTRAL, EASTERN & SOUTHERN EUROPE

17.1 MARKET OVERVIEW

17.2 MARKET SIZE & FORECAST

17.3 KEY COUNTRIES

17.3.1 NETHERLANDS: MARKET SIZE & FORECAST

17.3.2 PORTUGAL: MARKET SIZE & FORECAST

17.3.3 SWITZERLAND: MARKET SIZE & FORECAST

18 NORDICS

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.3 KEY COUNTRIES

18.3.1 SWEDEN: MARKET SIZE & FORECAST

18.3.2 DENMARK: MARKET SIZE & FORECAST

19 COMPETITIVE LANDSCAPE

19.1 COMPETITION OVERVIEW

19.2 MARKET SHARE ANALYSIS

19.2.1 F. HOFFMANN-LA ROCHE

19.2.2 QIAGEN

20 KEY COMPANY PROFILES

20.1 F. HOFFMANN-LA ROCHE

20.1.1 BUSINESS OVERVIEW

20.1.2 PRODUCT OFFERINGS

20.1.3 KEY STRATEGIES

20.1.4 KEY STRENGTHS

20.1.5 KEY OPPORTUNITIES

20.2 QIAGEN

21 OTHER PROMINENT VENDORS

21.1 ALTONA DIAGNOSTICS

21.1.1 BUSINESS OVERVIEW

21.1.2 PRODUCT OFFERINGS

21.2 AUTOBIO

21.3 APPLIED DNA SCIENCES

21.4 AURORA BIOMED

21.5 BIOACTIVA DIAGNOSTICA

21.6 BEIJING HOTGEN BIOTECH

21.7 BIOGX

21.8 CERTEST BIOTEC

21.9 CREATIVE BIOGENE

21.10 CORDX

21.11 CLONIT

21.12 EUROBIO SCIENTIFIC

21.13 FIREGENE

21.14 GENSCRIPT

21.15 GUANGZHOU PLUSLIFE BIOTECH

21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY

21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY

21.18 RAYBIOTECH LIFE

21.19 SANSURE BIOTECH

21.20 VIRAX BIOLABS

21.21 WONDFO

21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY

22 REPORT SUMMARY

22.1 KEY TAKEAWAYS

22.2 STRATEGIC RECOMMENDATIONS

23 QUANTITATIVE SUMMARY

23.1 MARKET BY GEOGRAPHY

23.2 MARKET BY TYPE

23.3 MARKET BY END-USER

24 APPENDIX

24.1 ABBREVIATIONS

About Us:   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.  

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  

Click Here to Contact Us  
Call: +1-312-235-2040  
          +1 302 469 0707  
Mail: [email protected]

Photo: https://mma.prnewswire.com/media/1999263/Europe_Monkey_Pox_Market.jpg
Logo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/europe-to-spend-usd-18-million-in-monkeypox-testing-by-the-end-of-2023–arizton-301743001.html

PR Newswire Science News